Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 4/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510285 | 1.00 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30510339 | 0.90 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL21837525 | 0.90 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL1869833 | 0.88 | FABP5 (0.50) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL27028700 | 0.88 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30792906 | 0.88 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31278102 | 0.86 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL21950699 | 0.86 | KMT2A (0.46) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL15083344 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30510293 | 0.84 | KMT2A (0.44) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-7094758-B2 | Apoptotic compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-08-22 | — | — | US | disclosed |
| US-7041784-B2 | Procaspase-3 activation; peptide comprising AX1 wherein X1 is V, I or L (alanine with valine, isoleucine or leucine) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-09 | — | — | US | disclosed |
| US-20060084611-A1 | Apoptotic compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2006-04-20 | — | — | US | disclosed |
| US-20040077542-A1 | Procaspase-3 activation; peptide comprising AX1 wherein X1 is V, I or L (alanine with valine, isoleucine or leucine) | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-04-22 | — | — | US | disclosed |
| US-6608026-B1 | Contacting pathogenic cells with AV peptoid which comprises amino acid sequence Ala-Val-Pro, is fewer than 20 residues in length, has molecular weight less than 1000, and interacts with Inhibitor of Apoptosis protein, to enhance apoptosis | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-08-19 | — | — | US | disclosed |
| WO-2002016402-A2 | APOPTOTIC COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-02-28 | — | — | WO | disclosed |
| EP-0535155-B1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | CHIRON CORP (US) | 2002-01-30 | — | — | EP | disclosed |
| US-6075121-A | HETEROPOLYMERIC PEPTOID COMPOUND CONSISTING OF 2 TO 50 N-SUBSTITUTED GLYCINES HAVING DIFFERENT ALPHA-AMINO R GROUPS; CAPABLE OF NON-NATURAL CONFIGURATIONS FOR DRUG DESIGN | CHIRON CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| US-5965695-A | PEPTOIDS COMPRISED OF 2-50 MONOMER UNITS INCLUDING AT LEAST 2 N-SUBSTITUTED GLYCINE RESIDUES; THE PEPTOIDS ARE CONJUGATED TO A DRUG SUCH AS AZT OR TRIMETHOPRIM, FOR INCREASED BINDING AFFINITY TO A PARTICULAR BIOLOGICAL RECEPTOR | CHIRON CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| US-5811387-A | ENZYME RESISTANT OLIGO- OR POLY-PEPTOID WHICH MAY SELECTIVELY BIND TO POLYPEPTIDE OR EFFECTOR MOLECULE; MIMETICS, PEPTOID LIBRARIES | CHIRON CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| EP-0535155-A4 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT PAUL A (US) | 1994-08-17 | — | — | EP | disclosed |
| EP-0535155-A1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT, Paul A. (US) | 1993-04-07 | — | — | EP | disclosed |
| WO-1991019735-A1 | LIBRARIES OF MODIFIED PEPTIDES WITH PROTEASE RESISTANCE | BARTLETT PAUL A (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | KMT2A 4757/4885FABP5 4026/4885FABP7 4376/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KMT2A 3145/4885FABP5 4094/4885FABP7 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.